Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A bigger IVD portfolio for Biofortuna
March 2017
SHARING OPTIONS:

BIRKENHEAD, U.K.—Biofortuna is seeking to boost its in-vitro diagnostic (IVD) service portfolio with an increased focus on the design, development and manufacture of immunoassays, with a significant investment in its production capabilities to include plate coating, washing, drying and quality control. Biofortuna’s existing molecular IVD service offerings include ISO 13485-accredited and FDA-registered contract research, lyophilisation, air-drying, manufacturing, dispensing and kitting of diagnostic products. The company also offers molecular diagnostic products for HLA disease identification and pharmacogenetics, and is developing real-time blood group genotyping kits.
 
“The success and growth of current projects has fueled the desire to increase our immunoassay offering. This expansion will allow for large-scale manufacturing of ELISA-based kits to meet our customers’ growing needs,” remarked Dr. Simon Douglas, CEO of Biofortuna.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.